Bone alkaline phosphatase and mortality in dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 7, 2011, Pages 1752-1759

  Drechsler, Christiane ^a,b   Verduijn, Marion ^a   Pilz, Stefan ^c   Krediet, Raymond T ^d   Dekker, Friedo W ^a   Wanner, Christoph ^b   Ketteler, Markus ^e   Boeschoten, Elisabeth W ^f   Brandenburg, Vincent ^g  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e KLINIKUM COBURG   (Germany)

^f Hans Mak Institute   (Netherlands)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CHOLESTEROL; CREATININE; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHORUS; UREA;

ADULT; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 79960333388     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10091110     Document Type: Article

References (28)

1. Block GA: Screening dialysis patients for vascular calcification. Semin Dial 23: 271-276, 2010
2. Floege J, Ketteler M: Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 19[Suppl 5]: V59-V66, 2004
3. Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J: Vitamin K deficiency in CKD patients: A modifiable risk factor for vascular calcification? Kidney Int 76: 18-22, 2009
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 113: S1-S130, 2009
5. Iba K, Takada J, Yamashita T: The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab 22: 594-596, 2004
6. Price PA, Toroian D, Chan WS: Tissue-nonspecific alkaline phosphatase is required for the calcification of collagen in serum: A possible mechanism for biomineralization. J Biol Chem 284: 4594-4604, 2009
7. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K: Outcome predictability of serum alkaline phosphatase in men with predialysis CKD. Nephrol Dial Transplant 25: 3003-3011, 2010
8. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van WD, Kopple JD, Kalantar-Zadeh K: Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19: 2193-2203, 2008
9. Shantouf R, Kovesdy CP, Kim Y, Ahmadi N, Luna A, Luna C, Rambod M, Nissenson AR, Budoff MJ, Kalantar-Zadeh K: Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 4: 1106-1114, 2009
10. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van H, V, De Broe ME, D'Haese PC: Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 41: 997-1007, 2003
11. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC: Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7: 506-512, 1996
12. Khan IH, Catto GR, Edward N, Fleming LW, Henderson IS, MacLeod AM: Influence of coexisting disease on survival on renal-replacement therapy. Lancet 341: 415-418, 1993
13. Southern DA, Faris PD, Brant R, Galbraith PD, Norris CM, Knudtson ML, Ghali WA: Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol 59: 1110-1114, 2006
14. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD: A note on competing risks in survival data analysis. Br J Cancer 91: 1229-1235, 2004
15. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, Wanner C, Boeschoten EW, Brandenburg V: Vitamin D status and clinical outcomes in incident dialysis patients: Results from the NECOSAD study. Nephrol Dial Transplant 26: 1024-1032, 2010
16. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, Marz W, Ritz E, Wanner C: Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 31: 2253-2261, 2010
17. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Jr., Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007
18. Urena P, Bernard-Poenaru O, Cohen-Solal M, de Vernejoul MC: Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol. Clin Nephrol 57: 261-273, 2002
19. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F: Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 13: 2294-2302, 1998
20. Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME: Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 11: 1065-1072, 1996
21. Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G: Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3-5. Clin Nephrol 70: 296-305, 2008
22. Moore C, Yee J, Malluche H, Rao DS, Monier-Faugere MC, Adams E, Ramola-Ogunwuyi O, Fehmi H, Bhat S, Osman-Malik Y: Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol 4: 1484-1493, 2009
23. Brandenburg V, Floege J: Adynamic bone disease: Bone and beyond. Nephrol Dial Transplant Plus 3: 135-147, 2008
24. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263-276, 2006
25. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM: Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 28: 97-106, 2008
26. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de FA, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant, 2010 December 10. [Epub ahead of print]
27. Schoppet M, Shanahan CM: Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int 73: 989-991, 2008
28. Towler DA: Inorganic pyrophosphate: A paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 25: 651-654, 2005